@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix mgi: . @prefix geneProductOf: . @prefix proteinModification: . @prefix psimod: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: mgi:96083; a Protein: . sub:_2 belv:variantOf mgi:95410; a proteinModification:, psimod:00696 . sub:_3 occursIn: species:10090; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(MGI:Nrg1) -> p(MGI:Erbb2,pmod(P))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "Blockage of ErbB2 expression by using antisense oligodeoxynucleotide of ErbB2 mRNA resulted in almost complete inhibition of HRG capacity to promote progesterone binding to DNA. HRG was also able to promote strong activation of PRE-CAT gene, which was abolished by treating cells with antisense oligodeoxynucleotides to ErbB2."; prov:wasQuotedFrom pubmed:12529413 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12529413; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:09.400+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }